HIV-infected children face unique challenges, such as; perinatal transmission of drug resistant HIV virus, limited safety data, impact of ARVs on their grown and development, need for different formulations and…
Read More
There is need for anti-malarial combination therapy (ACT) comprising of at least one partner drug with a new mechanism of action to reduce developing resistance. The purpose of this study…
Read More
This study enables continued access to Rilpivirine (RPV), for the evaluation of the long-term safety and tolerability of RPV in combination with other optimized background ARVs, in HIV-infected children aged…
Read More
This is an open-label single-arm study, that will provide continued access to study drug to participants who completed their participation in parent studies sponsored by Gilead Sciences US, which include;…
Read More
The aim was to test the safety, effectiveness, and pharmacokinetics of a new HIV medication, GS-9883. Participants received the new medication for 48 weeks.
Read More
Tenofovir disoproxil fumarate (TDF) is a preferred NRTI among recommended regimens for treatment-naive HIV-infected adults and adolescents, but is associated with nephrotoxicity and reduced bone mineral density. Lifelong antiretroviral treatment…
Read More
This study builds on research conducted in the early 2000s that examined the relationship between hormonal contraceptive use, genital tract microbiome diversity and HIV seroconversion. Archived biological samples from the…
Read More
